ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic

• Titel: ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic
• Titelzusatz: part 2 - care pathways, treatment, and follow-up
• Mitwirkende: Baigent, Colin [VerfasserIn]
• Mitwirkende: Katus, Hugo [VerfasserIn]
• Verf.angabe: The Task Force for the management of COVID-19 of the European Society of Cardiology*
• E-Jahr: 2022
• Jahr: 14 March 2022
• Umfang: 45 S.
• Fussnoten: Online veröffentlicht 16 November 2021 ; *The Task Force for the management of COVID-19 of the European Society of Cardiology: Colin Baigent, Hugo Katus [und viele weitere Personen] ; Gesehen am 02.02.2023
• Titel Quelle: Enthalten in: European heart journal
• Ort Quelle: Oxford : Oxford University Press, 1980
• Jahr Quelle: 2022
• Band/Heft Quelle: 43(2022), 11, Seite 1059-1103
• ISSN Quelle: 1522-9645
• DOI: doi:10.1093/eurheartj/ehab697
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1833056531

Abstract

Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19.A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19.This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.